Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling

Advances in Immunology

Volumn 114, Issue , 2012, Pages 151-176

  Wang, Helen Y ^a,b   Wang, Rong Fu ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cancer vaccines; Cell penetrating peptides; Immunological intervention; Immunotherapy; Innate immune signaling

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLOPHOSPHAMIDE; FLUDARABINE; GLYCOPROTEIN GP 100; HLA DR ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; MYELOID DIFFERENTIATION FACTOR 88; NY ESO 1 ANTIGEN; SIPULEUCEL T; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 8; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELL TRANSPORT; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOKINE ACTIVATED KILLER CELL; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; OVERALL SURVIVAL; PATTERN RECOGNITION; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84863354483     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-396548-6.00006-8     Document Type: Chapter

References (170)

1. Aarnoudse C.A., van den Doel P.B., Heemskerk B., Schrier P.I. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 1999, 82:442-448.
2. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Apetoh L., Locher C., Ghiringhelli F., Kroemer G., Zitvogel L. Harnessing dendritic cells in cancer. Semin. Immunol. 2011, 23:42-49.
4. Ayyoub M., Stevanovic S., Sahin U., Guillaume P., Servis C., Rimoldi D., Valmori D., Romero P., Cerottini J.C., Rammensee H.G., et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 2002, 168:1717-1722.
5. Bakker A.B.H., Schreurs M.W.J., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., Figdor C.G. Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J. Exp. Med. 1994, 179:1005-1009.
6. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
7. Benlalam H., Linard B., Guilloux Y., Moreau-Aubry A., Derre L., Diez E., Dreno B., Jotereau F., Labarriere N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 2003, 171:6283-6289.
8. Berry C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine 2008, 3:357-365.
9. Bickham K., Munz C., Tsang M.L., Larsson M., Fonteneau J.F., Bhardwaj N., Steinman R. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J. Clin. Invest. 2001, 107:121-130.
10. Bilusic M., Madan R.A. Therapeutic cancer vaccines: The latest advancement in targeted therapy. Am. J. Ther 2011, In Press (Epublication Feb. 2011).
11. Boel P., Wildmann C., Sensi M.L., Brasseur R., Renauld J.C., Coulie P., Boon T., Van der Bruggen P. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2:167-175.
12. Boon T., Cerottini J.-C., Van Den Eynde B., Van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994, 12:337-365.
13. Brichard V.G., Herman J., Van Pel A., Wildmann C., Gaugler B., Wolfel T., Boon T., Lethe B. A tyrosinase nonpeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 1996, 26:224-230.
14. Callahan M.K., Wolchok J.D., Allison J.P. Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 2010, 37:473-484.
15. Castelli C., Storkus W.J., Maeurer M.J., Martin D.M., Huang E.C., Pramanik B.N., Nagabhushan T.L., Parmiani G., Lotze M.T. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. 1995, 181:363-368.
16. Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L., Ravagnani F., Gallino F., Belli F., Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J. Immunol. 1999, 162:1739-1748.
17. Cecco S., Muraro E., Giacomin E., Martorelli D., Lazzarini R., Baldo P., Dolcetti R. Cancer vaccines in phase II/III clinical trials: State of the art and future perspectives. Curr. Cancer Drug Targets 2011, 11:85-102.
18. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 2001, 19:565-594.
19. Chaux P., Luiten R., Demotte N., Vantomme V., Stroobant V., Traversari C., Russo V., Schultz E., Cornelis G.R., Boon T., et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 1999, 163:2928-2936.
20. Chaux P., Vantomme V., Stroobant V., Thielemans K., Corthals J., Luiten R., Eggermont A.M., Boon T., van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 1999, 189:767-778.
21. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 1997, 94:1914-1918.
22. Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T., Coulie P.G. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 2000, 60:4855-4863.
23. Consogno G., Manici S., Facchinetti V., Bachi A., Hammer J., Conti-Fine B.M., Rugarli C., Traversari C., Protti M.P. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 2003, 101:1038-1044.
24. Coulie P.G., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C., Mattei S., De Plaen E.D., Lurquin C., Szikora J.-P., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994, 180:35-42.
25. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
26. Cox A.L., Skipper J., Cehn Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., Slingluff C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264:716-719.
27. Cui J., Zhu L., Xia X., Wang H.Y., Legras X., Hong J., Ji J., Shen P., Zheng S., Chen Z.J., et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010, 141:483-496.
28. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., Nakai Y., Isaacs W.B., Nelson W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7:256-269.
29. Delamarre L., Mellman I. Harnessing dendritic cells for immunotherapy. Semin. Immunol. 2011, 23:2-11.
30. Deshayes S., Morris M.C., Divita G., Heitz F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 2005, 62:1839-1849.
31. Diefenbach A., Raulet D.H. Strategies for target cell recognition by natural killer cells. Immunol. Rev. 2001, 181:170-184.
32. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 19:19.
33. Duffour M.T., Chaux P., Lurquin C., Cornelis G., Boon T., van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur. J. Immunol. 1999, 29:3329-3337.
34. Duthie M.S., Windish H.P., Fox C.B., Reed S.G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 2011, 239:178-196.
35. Edenhofer F. Protein transduction revisited: Novel insights into the mechanism underlying intracellular delivery of proteins. Curr. Pharm. Des. 2008, 14:3628-3636.
36. Fleischhauer K., Avila D., Vilbois F., Traversari C., Bordignon C., Wallny H.J. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: Implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. Tissue Antigens 1995, 44:311-317.
37. Fujie T., Tahara K., Tanaka F., Mori M., Takesako K., Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int. J. Cancer 1999, 80:169-172.
38. Gaugler B., Van Den Eynde B., Van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethe B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 1994, 179:921-930.
39. Greenberg P.D. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 1991, 49:281-355.
40. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 1982, 155:1823-1841.
41. Gupta B., Levchenko T.S., Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57:637-651.
42. Heidecker L., Brasseur F., Probst-Kepper M., Gueguen M., Boon T., Van den Eynde B.J. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J. Immunol. 2000, 164:6041-6045.
43. Herman J., van der Bruggen P., Luescher I.F., Mandruzzato S., Romero P., Thonnard J., Fleischhauer K., Boon T., Coulie P.G. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996, 43:377-383.
44. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
45. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011, 137:305-310.
46. Huang L.Q., Brasseur F., Serrano A., De Plaen E., van der Bruggen P., Boon T., Van Pel A. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 1999, 162:6849-6854.
47. Huang L.M., Lu C.Y., Chen D.S. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr. Opin. Immunol. 2011, 23:237-243.
48. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358:2698-2703.
49. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
50. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., Arand M., Wada H., Noguchi Y., Stockert E., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998, 187:265-270.
51. Jiang H., Liu K.Y., Tong C.R., Jiang B., Lu D.P. The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia. Zhonghua Nei Ke Za Zhi 2005, 44:198-201.
52. Kang X.-Q., Kawakami Y., Sakaguchi K., El-Gamil M., Wang R.-F., Yannelli J.R., Appella E., Rosenberg S.A., Robbins P.F. Identification of a tyrosinase epitope reocognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol. 1995, 155:1343-1348.
53. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
54. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
55. Kawakami Y., Eliyahu S., Delgaldo C.H., Robbins P.F., Rivoltini L., Topalian S.L., Miki T., Rosenberg S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 1994, 91:3515-3519.
56. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.B., Appella E., Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994, 180:347-352.
57. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Appella E., Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 1995, 154:3961-3968.
58. Kawakami Y., Robbins P.F., Wang X., Tupesis J.P., Parkhurst M.R., Kang X., Sakaguchi K., Appella E., Rosenberg S.A. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, - A2, and -A3 alleles. J. Immunol. 1998, 161:6985-6992.
59. Kawashima I., Tsai V., Southwood S., Takesako K., Celis E., Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int. J. Cancer 1998, 78:518-524.
60. Kiniwa Y., Miyahara Y., Wang H.Y., Peng W., Peng G., Wheeler T.M., Thompson T., Old L.J., Wang R.F. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 2007, 13:6947-6958.
61. Kittlesen D.J., Thompson L.W., Gulden P.H., Skipper J.C., Colella T.A., Shabanowitz J., Hunt D.F., Engelhard V.H., Slingluff C.L., Shabanowitz J.A. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J. Immunol. 1998, 160:2099-2106.
62. Kobayashi H., Kokubo T., Takahashi M., Sato K., Miyokawa N., Kimura S., Kinouchi R., Katagiri M. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998, 47:398-403.
63. Kobayashi H., Lu J., Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001, 61:7577-7584.
64. Kobayashi H., Song Y., Hoon D.S., Appella E., Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001, 61:4773-4778.
65. Kwak K., Yemelyanova A., Roden R.B. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr. Opin. Immunol. 2011, 23:244-251.
66. Lapointe R., Royal R.E., Reeves M.E., Altomare I., Robbins P.F., Hwu P. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J. Immunol. 2001, 167:4758-4764.
67. Leen A., Meij P., Redchenko I., Middeldorp J., Bloemena E., Rickinson A., Blake N. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol. 2001, 75:8649-8659.
68. Leen A.M., Myers G.D., Sili U., Huls M.H., Weiss H., Leung K.S., Carrum G., Krance R.A., Chang C.C., Molldrem J.J., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 2006, 12:1160-1166.
69. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 2007, 25:243-265.
70. Lesterhuis W.J., Haanen J.B., Punt C.J. Cancer immunotherapy-Revisited. Nat. Rev. Drug Discov. 2011, 10:591-600.
71. Linn Y.C., Lau L.C., Hui K.M. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br. J. Haematol. 2002, 116:78-86.
72. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 2006, 103:7048-7053.
73. Long H.M., Taylor G.S., Rickinson A.B. Immune defence against EBV and EBV-associated disease. Curr. Opin. Immunol. 2011, 23:258-264.
74. Lupetti R., Pisarra P., Verrecchia A., Farina C., Nicolini G., Anichini A., Bordignon C., Sensi M., Parmiani G., Traversari C. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 1998, 188:1005-1016.
75. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 1997, 186:785-793.
76. Manicassamy S., Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 2009, 21:185-193.
77. Manici S., Sturniolo T., Imro M.A., Hammer J., Sinigaglia F., Noppen C., Spagnoli G., Mazzi B., Bellone M., Dellabona P., et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 1999, 189:871-876.
78. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. Int. J. Cancer 1999, 80:219-230.
79. Marshall N.A., Vickers M.A., Barker R.N. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J. Immunol. 2003, 170:6183-6189.
80. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008, 8:351-360.
81. Munz C., Bickham K.L., Subklewe M., Tsang M.L., Chahroudi A., Kurilla M.G., Zhang D., O'Donnell M., Steinman R.M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 2000, 191:1649-1660.
82. Muul L.M., Nason-Burchenal K., Carter C.S., Cullis H., Slavin D., Hyatt C., Director E.P., Leitman S.F., Klein H.G., Rosenberg S.A. Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. J. Immunol. Methods 1987, 101:171-181.
83. Netea M.G., Sutmuller R., Hermann C., Van der Graaf C.A., Van der Meer J.W., van Krieken J.H., Hartung T., Adema G., Kullberg B.J. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J. Immunol. 2004, 172:3712-3718.
84. Noppen C., Levy F., Burri L., Zajac P., Remmel E., Schaefer C., Luscher U., Heberer M., Spagnoli G.C. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int. J. Cancer 2000, 87:241-246.
85. Nyirenda M.H., Sanvito L., Darlington P.J., O'Brien K., Zhang G.X., Constantinescu C.S., Bar-Or A., Gran B. TLR2 Stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function. J. Immunol. 2011, 187:2278-2290.
86. Oberg H.H., Ly T.T., Ussat S., Meyer T., Kabelitz D., Wesch D. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J. Immunol. 2010, 184:4733-4740.
87. Oiso M., Eura M., Katsura F., Takiguchi M., Sobao Y., Masuyama K., Nakashima M., Itoh K., Ishikawa T. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int. J. Cancer 1999, 81:387-394.
88. Paludan C., Munz C. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus. Curr. Mol. Med. 2003, 3:341-347.
89. Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y., Robbins P., Riker A., Rosenberg S.A., Marincola F.M. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 2000, 164:4382-4392.
90. Parkhurst M.R., Fitzgerald E.B., Southwood S., Sette A., Rosenberg S.A., Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998, 58:4895-4901.
91. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., Wang D.Y., Li Y., Wang H.Y., Wang R.-F. Toll-like receptor 8 mediated-reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
92. Peng G., Wang H.Y., Peng W., Kiniwa Y., Seo K., Wang R.-F. Tumor-infiltrating gamma-delta T cells suppress T and dendritic cell function via mechanisms controlled by a unique Toll-like receptor signaling pathway. Immunity 2007, 27:334-348.
93. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001, 411:390-395.
94. Pieper R., Christian R.E., Gonzales M.I., Nishimura M.I., Gupta G., Settlage R.E., Shabanowitz J., Rosenberg S.A., Hunt D.F., Topalian S.L. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J. Exp. Med. 1999, 189:757-766.
95. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., Rosenberg S.A. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 1996, 183:1185-1192.
96. Robbins P., El-Gamil M., Li Y.F., Fitzgerald E., Kawakami Y., Rosenberg S.A. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J. Immunol. 1997, 159:303-308.
97. Rosenberg S.A. Adoptive immunotherapy for cancer. Sci. Am. 1990, 262:62-69.
98. Rosenberg S.A. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 2000, 6(Suppl. 1):S2-S7.
99. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 2011, 8:577-585.
100. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 1987, 316:889-897.
101. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A., et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A Preliminary report. N. Engl. J. Med. 1988, 319:1676-1680.
102. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
103. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., et al. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4:321-327.
104. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: Moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
105. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
106. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
107. Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011, 332:974-977.
108. Royal R.E., Levy C., Turner K., Mathur A., Hughes M., Kammula U.S., Sherry R.M., Topalian S.L., Yang J.C., Lowy I., et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 2010, 33:828-833.
109. Russo V., Tanzarella S., Dalerba P., Rigatti D., Rovere P., Villa A., Bordignon C., Traversari C. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl. Acad. Sci. USA 2000, 97:2185-2190.
110. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991, 174:139-149.
111. Schneider J., Brichard V., Boon T., Meyer zum Buschenfelde K.H., Wolfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART- 1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 1998, 75:451-458.
112. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
113. Schroers R., Huang X.F., Hammer J., Zhang J., Chen S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002, 62:2600-2605.
114. Schultz E.S., Lethe B., Cambiaso C.L., Van Snick J., Chaux P., Corthals J., Heirman C., Thielemans K., Boon T., van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000, 60:6272-6275.
115. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119-2127.
116. Sensi M., Pellegatta S., Vegetti C., Nicolini G., Parmiani G., Anichini A. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. Tissue Antigens 2002, 59:273-279.
117. Skipper J.C., Kittlesen D.J., Hendrickson R.C., Deacon D.D., Harthun N.L., Wagner S.N., Hunt D.F., Engelhard V.H., Slingluff C.L. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 1996, 157:5027-5033.
118. Slager E.H., Borghi M., van der Minne C.E., Aarnoudse C.A., Havenga M.J., Schrier P.I., Osanto S., Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: A tumor antigen translated in an alternative open reading frame. J. Immunol. 2003, 170:1490-1497.
119. Song X.T., Evel-Kabler K., Shen L., Rollins L., Huang X.F., Chen S.Y. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 2008, 14:258-265.
120. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., Arand M., Knuth A., Old L.J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998, 187:1349-1354.
121. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., Joosten L.A., Akira S., Netea M.G., Adema G.J. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 2006, 116:485-494.
122. Tacken P.J., Figdor C.G. Targeted antigen delivery and activation of dendritic cells in vivo: Steps towards cost effective vaccines. Semin. Immunol. 2011, 23:12-20.
123. Tahara K., Takesako K., Sette A., Celis E., Kitano S., Akiyoshi T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 1999, 5:2236-2241.
124. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., Shimada K., Sakamoto M., Hirohashi S., Ohashi Y., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000, 356:802-807.
125. Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005, 17:1-14.
126. Tanaka F., Fujie T., Tahara K., Mori M., Takesako K., Sette A., Celis E., Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. 1997, 57:4465-4468.
127. Tanzarella S., Russo V., Lionello I., Dalerba P., Rigatti D., Bordignon C., Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999, 59:2668-2674.
128. Tey S.K., Bollard C.M., Heslop H.E. Adoptive T-cell transfer in cancer immunotherapy. Immunol. Cell Biol. 2006, 84:281-289.
129. Topalian S.L., Gonzales M.I., Parkhurst M., Li Y.F., Southwood S., Sette A., Rosenberg S.A., Robbins P.F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 1996, 183:1965-1971.
130. Topalian S.L., Gonzales M.I., Ward Y., Wang X., Wang R.F. Revelation of a cryptic major histocompatibility complex class II- restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 2002, 62:5505-5509.
131. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
132. Touloukian C.E., Leitner W.W., Topalian S.L., Li Y.F., Robbins P.F., Rosenberg S.A., Restifo N.P. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol. 2000, 164:3535-3542.
133. Traversari C., Van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992, 176:1453-1457.
134. Tsai V., Southwood S., Sidney J., Sakaguchi K., Kawakami Y., Appella E., Sette A., Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997, 158:1796-1802.
135. Van der Bruggen P., Traversari C., Chomez P., Lurquin C., DePlaen E., Van Den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
136. Van der Bruggen P., Bastin J., Gajewski T., Coulie P.G., Boel P., de Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 1994, 24:3038-3043.
137. Van der Bruggen P., Szikora J.-P., Boel P., Wildmann C., Somville M., Sensi M., Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur. J. Immunol. 1994, 24:2134-2140.
138. van der Burg S.H., Melief C.J. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 2011, 23:252-257.
139. Vence L., Palucka A.K., Fay J.W., Ito T., Liu Y.J., Banchereau J., Ueno H. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 2007, 104:20884-20889.
140. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
141. Visseren M.J., van der Burg S.H., van der Voort E.I., Brandt R.M., Schrier P.I., van der Bruggen P., Boon T., Melief C.J., Kast W.M. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer 1997, 73:125-130.
142. Voo K.S., Fu T., Heslop H.E., Brenner M.K., Rooney C.M., Wang R.F. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002, 62:7195-7199.
143. Voo K.S., Peng G., Guo Z., Fu T., Li Y., Frappier L., Wang R.F. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 2005, 65:1577-1586.
144. Wang R.-F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001, 22:269-276.
145. Wang R.F., Rosenberg S.A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 1999, 170:85-100.
146. Wang R.-F., Wang H.Y. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 2002, 20:149-156.
147. Wang R.-F., Appella E., Kawakami Y., Kang X., Rosenberg S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 1996, 184:2207-2216.
148. Wang R.-F., Parkhurst M.R., Kawakami Y., Robbins P.F., Rosenberg S.A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 1996, 183:1131-1140.
149. Wang R.-F., Johnston S., Southwood S., Sette A., Rosenberg S.A. Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33. J. Immunol. 1998, 160:890-897.
150. Wang R.-F., Johnston S.L., Zeng G., Schwartzentruber D.J., Rosenberg S.A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 1998, 161:3596-3606.
151. Wang R.-F., Wang X., Atwood A.C., Topalian S.L., Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999, 284:1351-1354.
152. Wang R.-F., Wang X., Rosenberg S.A. Identification of a novel MHC class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J. Exp. Med. 1999, 189:1659-1667.
153. Wang H.Y., Fu T., Wang G., Gang Z., Donna M.P.-L., Yang J.C., Restifo N.P., Hwu P., Wang R.-F. Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 2002, 109:1463-1470.
154. Wang H.Y., Zhou J., Zhu K., Riker A.I., Marincola F.M., Wang R.-F. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: Its role in extracellular matrix formation and tumor metastasis. J. Exp. Med. 2002, 195:1397-1406.
155. Wang H.Y., Lee D.A., Peng G., Guo Z., Li Y., Kiniwa Y., Shevach E.M., Wang R.-F. Tumor-specific human CD4+ regulatory T cells and their ligands: Implication for immunotherapy. Immunity 2004, 20:107-118.
156. Wang H.Y., Peng G., Guo Z., Shevach E.M., Wang R.-F. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 2005, 174:2661-2670.
157. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9:606-612.
158. Wolfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Meyer Zum Buschenfelde K.-H., Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 1994, 24:759-764.
159. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer Zum Buschenfelde K.-H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
160. Wrzesinski C., Paulos C.M., Kaiser A., Muranski P., Palmer D.C., Gattinoni L., Yu Z., Rosenberg S.A., Restifo N.P. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 2010, 33:1-7.
161. Xia X., Cui J., Wang H.Y., Zhu L., Matsueda S., Wang Q., Yang X., Hong J., Songyang Z., Chen Z., et al. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011, 34:843-853.
162. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 2000, 192:1637-1644.
163. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002, 99:16168-16173.
164. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004, 5:730-737.
165. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
166. Zarour H.M., Kirkwood J.M., Kierstead L.S., Herr W., Brusic V., Slingluff C.L., Sidney J., Sette A., Storkus W.J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA 2000, 97:400-405.
167. Zeng G., Touloukian C.E., Wang X., Restifo N.P., Rosenberg S.A., Wang R.-F. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 2000, 165:1153-1159.
168. Zeng G., Wang X., Robbins P.F., Rosenberg S.A., Wang R.-F. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA-DP4 allele: Association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 2001, 98:3964-3969.
169. Zhu Y., Yao S., Chen L. Cell surface signaling molecules in the control of immune responses: A tide model. Immunity 2011, 34:466-478.
170. Zorn E., Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol. 1999, 29:602-607.